ISO 10993-1 Revision: Updating Your Biological Evaluation Strategy

Navigating the ISO 10993-1 Revision: A Guide to Updating Your Biological Evaluation Strategy The upcoming revision to ISO 10993-1, the foundational standard for the biological evaluation of medical devices, represents a significant evolution in regulatory expectations. This update moves beyond a simple checklist of prescribed tests and solidifies the shift toward a comprehensive, risk-based, and lifecycle-oriented approach. For medical device manufacturers, this means that a compliant biological evaluation strategy requires more than just updated test protocols; it demands an integrated risk management process supported by robust scientific justification and objective evidence. Successfully navigating this change involves understanding how to leverage chemical characterization, justify testing strategies, and manage documentation across the entire material supply chain. This article provides a detailed breakdown of the critical adjustments needed to align your biological evaluation plan (BEP) and report (BER) with the revised standard, ensuring your device meets the expectations of regulators like the FDA and EU Notified Bodies. ### Key Points * **Risk Management as the Foundation:** The revision elevates the risk management process from a preliminary step to the central, ongoing framework that governs all biocompatibility activities. Every decision, from material selection to test omission, must be documented within this framework. * **Emphasis on Chemical Characterization:** There is an increased focus on comprehensive chemical characterization, particularly extractables and leachables (E&L) studies, as a primary method for understanding material safety and proactively identifying potential hazards. * **Justification is Paramount:** The burden of proof is firmly on the manufacturer to provide a robust scientific rationale for the entire evaluation strategy. This includes justifying the omission of any biological tests recommended by the standard. * **A Lifecycle Approach:** Biocompatibility is no longer a one-time, premarket activity. It is an ongoing process that must account for changes in manufacturing, suppliers, sterilization, and post-market surveillance data throughout the device's lifecycle. * **Supply Chain Scrutiny:** Regulators expect detailed documentation of the entire material supply chain. This includes characterizing raw materials, processing aids, colorants, and sterilization residuals to build a complete toxicological profile. * **Gap Analysis for Legacy Devices:** Existing devices are not exempt. Manufacturers must conduct a thorough gap analysis of their legacy device data against the revised standard's requirements, which may trigger the need for additional evaluation. ### The Shift from Checklist to Integrated Risk Management Historically, some manufacturers approached ISO 10993-1 as a checklist, performing the tests prescribed in the matrix for their device category and contact duration. The revised standard firmly cements the principle that biological evaluation is an integral part of the overall risk management process, as described in ISO 14971. This means the Biological Evaluation Plan (BEP) is no longer a static document but a living plan that evolves. It should begin early in the device design phase and be updated throughout the product lifecycle. A modern, compliant biological evaluation process includes: 1. **Material Characterization:** Gathering comprehensive information about all materials and processing agents used in the device. 2. **Hazard Identification:** Identifying potential biological risks associated with the materials, processing, and intended use of the device. 3. **Risk Estimation:** Evaluating the probability and severity of potential harm from each identified hazard. 4. **Data Gathering:** Using existing data, literature, and targeted testing (chemical, *in vitro*, and *in vivo*) to fill knowledge gaps. 5. **Risk Evaluation & Control:** Assessing whether the risks are acceptable. If not, implementing risk controls (e.g., changing a material) and re-evaluating. 6. **Final Reporting:** Summarizing the entire process, including all data and justifications, in a comprehensive Biological Evaluation Report (BER). This process must be continuous. A change in a material supplier, a modification to the sterilization process, or new post-market data could all trigger a re-evaluation of the device's biological safety. ### Deep Dive: Chemical Characterization and Toxicological Risk Assessment A central theme of the ISO 10993-1 revision is the increased reliance on chemical characterization (as detailed in ISO 10993-18) to inform the biological evaluation. The goal is to understand *what* chemicals could potentially be released from a device and then assess their toxicological risk, rather than simply observing the outcome of an animal test. #### Expectations for Extractables and Leachables (E&L) Studies Regulators now expect more rigorous E&L studies. This involves extracting chemicals from the device using solvents that simulate clinical use conditions and then identifying and quantifying them using sensitive analytical techniques. Key considerations include: * **Exaggerated and Exhaustive Extractions:** The study design must justify the extraction conditions (solvents, temperature, duration) to ensure they represent a worst-case scenario for patient exposure. * **Analytical Evaluation Threshold (AET):** This is a critical concept. The AET is a dose-based threshold below which a leachable is presumed to have a negligible toxicological risk. Any compound detected at or above the AET requires identification and a toxicological risk assessment. Calculating an accurate AET is essential for scoping the study appropriately. * **Toxicological Risk Assessment:** Once compounds are identified, a qualified toxicologist must assess their risk based on the potential patient exposure dose. This assessment determines whether the presence of these chemicals is acceptable or if further biological testing is needed to evaluate specific endpoints like genotoxicity or carcinogenicity. ### Justifying Test Omissions and Addressing Biological Endpoints One of the most powerful applications of a robust risk assessment and chemical characterization is the ability to scientifically justify the omission of certain *in vivo* biological tests. Regulators may accept a well-reasoned rationale in lieu of animal testing, but the justification must be robust. A strong justification for omitting a test typically includes: * **Comprehensive Material Data:** Detailed information on the material's composition, processing, and history of safe use in similar medical devices. * **Negative Chemistry Results:** E&L data showing that no toxicologically significant compounds are released at levels that would pose a risk. * **Relevant Existing Data:** Leveraging clinical data, literature, or biocompatibility results from a similar legally marketed device made of the identical material and processed identically. * **Favorable *In Vitro* Results:** Using data from *in vitro* tests (e.g., cytotoxicity) to support the absence of broader toxicity. For devices with novel materials, coatings, or manufacturing processes (e.g., 3D printing with new polymers), a justification for omitting tests is much more difficult. In these cases, regulators will expect a more complete suite of biological endpoint testing to establish a baseline safety profile. ### A Framework for Legacy Device Gap Analysis Manufacturers cannot assume that devices already on the market are compliant with the revised standard. A formal gap analysis is necessary to assess and update the documentation. A practical framework includes the following steps: 1. **Assemble Existing Documentation:** Gather the original BER and all supporting biocompatibility data, material specifications, and processing information for the legacy device. 2. **Map to the Revised Standard:** Create a checklist or table comparing each clause of the revised ISO 10993-1 against the existing data and rationale. 3. **Identify Gaps:** Systematically identify any shortfalls. Common gaps include: * An outdated risk assessment that doesn't align with the new standard's requirements. * Insufficient chemical characterization data. * Poorly documented justifications for test omissions. * Incomplete information on processing aids or sterilization residuals. 4. **Develop a Remediation Plan:** For each identified gap, create an action plan. This could involve commissioning new E&L testing, engaging a toxicologist to write an updated risk assessment, or contacting suppliers for more detailed material information. 5. **Assess the Regulatory Impact:** Based on the gap analysis, determine if the findings trigger the need for a new regulatory submission. According to **FDA guidance**, significant changes to materials or processes that could affect safety and effectiveness may require a new 510(k). Minor documentation updates may be handled with an internal letter-to-file. ### Strategic Considerations and the Role of Q-Submission Given the increased complexity and emphasis on justification, early engagement with regulators is more valuable than ever. For devices intended for the U.S. market, the FDA's Q-Submission program is an invaluable tool. Sponsors can use a Q-Submission to present their proposed Biological Evaluation Plan (BEP) to the FDA *before* initiating costly and time-consuming tests. This is particularly useful for: * Devices made from novel materials or with unique manufacturing processes. * Strategies that rely heavily on chemical characterization and toxicological risk assessment to justify omitting *in vivo* tests. * Complex devices where the appropriate biological endpoints are not immediately obvious. Obtaining FDA feedback on the testing strategy upfront can prevent significant delays and reduce the risk of receiving requests for additional information during the final submission review. ### Finding and Comparing Biocompatibility Testing Services Providers Choosing the right laboratory partner is critical for executing a compliant biological evaluation. A qualified provider does more than just run tests; they act as a strategic partner who understands the nuances of the standards and regulatory expectations. When evaluating potential providers, manufacturers should look for: * **Accreditation and Compliance:** The lab must be ISO/IEC 17025 accredited and operate under Good Laboratory Practice (GLP) where required (as stipulated in 21 CFR Part 58). * **Integrated Expertise:** Look for a provider with in-house expertise across chemistry, toxicology, and biology. This ensures a seamless process from E&L study design to toxicological risk assessment. * **Regulatory Experience:** The provider should have extensive experience with submissions to major regulatory bodies, including the FDA and EU Notified Bodies, and understand their specific expectations. * **Consultative Approach:** A strong partner will help design a testing strategy, calculate the AET, and interpret complex data to support the final BER. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ### Key FDA References When developing a biological evaluation strategy for the U.S. market, it is essential to consult the relevant regulations and guidance documents. While specific requirements are detailed across numerous device-specific guidances, the following are broadly applicable: * **FDA Guidance:** Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process." * **FDA Guidance:** Q-Submission Program Guidance. * **Code of Federal Regulations (CFR):** 21 CFR Part 807, Subpart E (Premarket Notification Procedures), which outlines submission requirements that include biocompatibility data. Sponsors should always refer to the FDA website for the latest versions of these documents. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*